Artículo
Patient-reported outcome measures in severe asthma: an expert consensus
Autor/es | Martínez Moragón, Eva
Antepara Ercoreca, Ignacio Muñoz García, María Casas Maldonado, Francisco Calvín Lamas, Marta Chiner Vives, Eusebi Merino Bohórquez, Vicente Sánchez Cuellar, Silvia |
Departamento | Universidad de Sevilla. Departamento de Farmacología |
Fecha de publicación | 2023-12-16 |
Fecha de depósito | 2024-04-05 |
Publicado en |
|
Resumen | Objective
The study aimed to reach a consensus on the most relevant patient-reported outcomes (PROs), the corresponding measures (PROMs), and measurement frequency during severe asthma patient follow-up.
Methods
Two ... Objective The study aimed to reach a consensus on the most relevant patient-reported outcomes (PROs), the corresponding measures (PROMs), and measurement frequency during severe asthma patient follow-up. Methods Two Delphi rounds were conducted. The questionnaire was developed based on a systematic literature review, a focus group with patients, and a nominal group with experts. It assessed PROs’ relevance and the appropriateness (A) and feasibility (F) of PROMs using a Likert scale (1=totally agree; 9=totally disagree). The consensus was established when ≥75% of participants agreed (1-3) or disagreed (7-9). Results Sixty-three professionals (25 hospital pharmacists, 14 allergists, 13 pulmonologists, and 11 nurses) and 5 patients answered the Delphi questionnaire. A consensus was reached on all PROs regarding their relevance. Experts agreed on the use of ACT (A:95.24%; F:95.24%), mini AQLQ (A:93.65; F:79.37%), mMRC dyspnea scale (A:85.71%; F:85.71%), TAI (A:92.06%; F:85.71%), MMAS (A:75.40%; F:82%), and the dispensing register (A:96.83%; F:92.06%). Also considered suitable were: SNOT-22 (A:90.48%; F:73.80%), PSQI (A:82.54; F:63.90%), HADS (A:82.54; F:64%), WPAI (A:77.78%; F:49.20%), TSQM-9 (A:79.37; F:70.50%) and knowledge of asthma questionnaire (A:77%; F:68.80%); however, their use in clinical practice was considered unfeasible. Panelists also agreed on the appropriateness of EQ-5D, which was finally included despite being considered unfeasible (A: 84.13%; F:67.20%) in clinical practice. Agreement was reached on using ACT, TAI, mMRC, and a dispensing register every three months; mini-AQLQ and MMAS every six months; and EQ-5D every twelve months. Conclusion This consensus paves the way toward patient-centered care, promoting the development of strategies supporting routine assessment of PROs in severe asthma management. |
Agencias financiadoras | GlaxoSmithKline GSK |
Cita | Martínez Moragón, E., Antepara Ercoreca, I., Muñoz García, M., Casas Maldonado, F., Calvín Lamas, M., Chiner Vives, E.,...,Sánchez Cuellar, S. (2023). Patient-reported outcome measures in severe asthma: an expert consensus. Journal of Asthma, 20023. https://doi.org/10.1080/02770903.2023.2297372. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Patient-reported outcome measures ... | 3.056Mb | [PDF] | Ver/ | |